# US 6,730,297 B1 · Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,297 B1
- Document ID: US6730297B1
- Status: Granted
- Kind: B1
- Application number: 09/580,820
- Filed: 2000-05-26
- Granted: 2004-05-04
- Earliest claimed: 1999-05-28
- Assignees: Chiron Corporation; University of Iowa Research Foundation
- Inventors: Beverly Davidson; Douglas J. Jolly; Sybille L. Sauter; Colleen S. Stein; Thomas W. Dubensky, Jr.; Jason A. Heth
- Web page: https://patentgrep.com/patent/US6730297B1

## CPC

- C12N 15/86: Viral vectors
- C12N 9/2434: {acting on beta-1,4-glucosidic bonds}
- C12Y 302/01018: Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
- C12Y 302/01031: Beta-glucuronidase (3.2.1.31)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Gene delivery vectors, for example, recombinant FIV vectors, and methods of using such vectors are provided for use in treating or preventing retinal diseases of the eye and diseases of the brain associated with lysosomal storage disorders.

## Claims

### Claim 1

An FIV vector, comprising a 5′ FIV LTR, a tRNA binding site, a packaging signal, a promoter operably linked to a polynucleotide encoding a protein selected from the group consisting of β-glucuronidase, neuraminidase, sphingomyelinase, sulfatase, arylsulfatase β, α-neuraminidase, gangliosidase, tripeptidyl protease, CLN3, and palmitoyl protein thioesterase (PPT), an origin of second strand DNA synthesis and a 3′ FIV LTR, wherein the FIV vector is devoid of vif and ORF 2.

### Claim 2 (depends on 1)

The FIV vector of claim 1, wherein the protein is β-glucuronidase.

### Claim 3 (depends on 1)

An FIV vector particle comprising the FIV vector of claim 1.

### Claim 4 (depends on 3)

A host cell transduced with the FIV vector particle of claim 3.

### Claim 5

An FIV vector comprising a 5′ FIV LTR, a tRNA binding site, a packaging signal, a polynucleotide encoding β-glucuronidase operably linked to an FIV LTR promoter or a promoter element, an origin of second strand DNA synthesis and a 3′ FIV LTR, wherein the FIV vector is devoid of vif and ORF 2.

### Claim 6 (depends on 5)

The FIV vector of claim 5, wherein the promoter element is a CMV, RSV or SV40 promoter.

### Claim 7 (depends on 5)

An FIV vector particle comprising the FIV vector of claim 5.

### Claim 8 (depends on 7)

A host cell transduced with the FIV vector particle of claim 7.

### Claim 9 (depends on 7)

A method of treating a glucuronidase-related lysosomal storage disorder of the eye or brain comprising providing the FIV vector particle of claim 7 to a vertebrate subject, wherein the FIV vector particle is administered to the subject in vivo, intravitreally, intraventricularly or via the striatum under conditions whereby the protein encoded by the polynucleotide is expressed in a cell of the vertebrate subject and secreted at a level sufficient to treat the lysosomal storage disorder.

### Claim 10 (depends on 9)

The method of claim 9, wherein said lysosomal storage disorder is a disorder of the eye and is selected from the group consisting of macular degeneration, diabetic retinopathy, and inherited retinal degeneration.

### Claim 11 (depends on 9)

The method of claim 9, wherein the lysosomal storage disorder is of the eye and the FIV vector particle is administered intravitreally.

### Claim 12 (depends on 9)

The method of claim 9, wherein the lysosomal storage disorder is of the brain and the FIV vector particle is administered intraventricularly.

### Claim 13 (depends on 9)

The method of claim 9, wherein the lysosomal storage disorder is of the brain and the FIV vector particle is administered via the striatum.
